Biotech | December 28, 2024
Department of Biotechnology hosts webinar on biomanufacturing of enzymes
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
